SCHEMBL11299433

SCHEMBL11299433

Fc1ccc(Nc2ncc3c(n2)-c2ccccc2CCC3)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.71
CYP1A2 P05177 3/20 0.60
CYP3A4 P08684 3/20 0.60
HTT P42858 1/20 0.60
CCNA2 P20248 5/20 0.56
CDK2 P24941 5/20 0.56
KDR P35968 5/20 0.49
CYP2C19 P33261 2/20 0.49
GAA P10253 1/20 0.49
CDK5 Q00535 1/20 0.49
CDK5R1 Q15078 1/20 0.49
LMNA P02545 1/20 0.47
KDM4E B2RXH2 2/20 0.46
AURKA O14965 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11296744 0.89 IKBKB (0.73) IKBKBCYP1A2CYP3A4CCNA2CDK2
SCHEMBL11296762 0.87 IKBKB (0.71) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL13439677 0.87 IKBKB (0.71) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL11299366 0.87 IKBKB (0.71) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL11296164 0.85 CDK2 (0.58) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL11312691 0.84 IKBKB (0.70) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL2434868 0.84 CDK2 (0.74) IKBKBCYP1A2CYP3A4HTTCCNA2
SCHEMBL11297579 0.83 IKBKB (1.00) IKBKBCCNA2CDK2CDK5CDK5R1
SCHEMBL11296777 0.82 IKBKB (0.71) IKBKBCYP1A2CYP3A4CCNA2CDK2
SCHEMBL13439675 0.80 IKBKB (0.61) IKBKBCYP1A2CYP3A4HTTCCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-8288400-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-16 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017619-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-04 US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 US disclosed
EP-1692140-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280026-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CYP1A2 4630/4885CYP3A4 4662/4885
US-20120183577-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K6 IKBKB 540/4885CYP1A2 4630/4885CYP3A4 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.